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Background: The study was conducted to evaluate the clinical and computed
tomography (CT) findings of non-small cell lung cancer (NSCLC) patients to
distinguish between ALK gene rearrangement, EGFR mutation, and non-ALK/
EGFR (no genetic abnormalities).
Methods: We enrolled 201 patients with primary NSCLC who had undergone
molecular testing for both ALK gene rearrangement and EGFR mutation. The
clinical features and CT findings of the main lesion and associated pulmonary
abnormalities were investigated.
Results: Female gender (P = 0.0043 vs. non-ALK/EGFR), young age (P = 0.0156
vs. EGFR), and a light or never smoking history (P = 0.0039 vs. non-ALK/EGFR)
were significant clinical characteristics of NSCLC with ALK gene rearrangement.
The significant CT characteristics compared to NSCLC with EGFR mutation
were a large mass (P = 0.0155), solid mass (P = 0.0048), and no air bronchogram
(P = 0.0148). A central location (P = 0.0322) and lymphadenopathy
(P = 0.0353) were also more frequently observed. Coexisting emphysema was
significantly less frequent in NSCLC patients with ALK gene rearrangement
(P = 0.0135) than non-ALK/EGFR.
Conclusions: NSCLC with ALK gene rearrangement was more likely to develop
in younger women with a light or never smoking history. The characteristic CT
findings of NSCLC with ALK gene rearrangement were a large solid mass, less
air bronchogram, a central location, and lymphadenopathy.
Introduction
Lung cancer is the leading cause of cancer-related death
worldwide. Recently, lung cancer treatment has undergone
remarkable changes. Some genetic abnormalities of non-
small cell lung cancer (NSCLC) can be diagnosed from tis-
sue samples,1–3 and effective small-molecule tyrosine kinase
inhibitors (TKIs) have enabled individualized treatment for
subgroups that are sensitive to ALK and EGFR
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inhibitors.4–6 These genetic abnormalities can be deter-
mined by specific analyses of histological samples obtained
by invasive procedures, including biopsy or surgical resec-
tion. In general, ALK gene rearrangement and EGFR muta-
tion are mutually exclusive: they are not present at the
same time.7–9 Therefore, it would be beneficial to clarify
the radiological features of each molecular subtype to
determine when such invasive diagnostic procedures are
warranted.
ALK rearrangements occur in 5% of NSCLC cases in
East Asian countries.6 They typically occur in younger
patients with a history of light or never smoking.6 ALK-
positive NSCLC is common among adenocarcinomas, and
is associated with the solid histological subtypes. Therefore,
these tumors tend to present on thin-section computed
tomography (CT) as a solid mass with little or no ground-
glass opacity (GGO) components.8,10 In addition, according
to previous studies, tumors with ALK gene rearrangement
tend to be centrally located, relatively large masses without
a cavity or pleural indentation.11–13 They may have a high
incidence of associated pleural effusion, carcinomatous
lymphangiosis, and lymphadenopathy.12,14–16 However,
there has been no consensus on imaging findings for ALK-
positive NSCLC.
The aim of this study was to evaluate the clinical and
CT findings of NSCLC with ALK gene rearrangement that
may enable distinction from NSCLC with EGFR mutation
or with neither genetic abnormality.
Methods
Study population
We retrospectively searched our cancer database for
patients who were diagnosed with primary NSCLC and
had undergone molecular testing for both ALK gene rear-
rangement and EGFR mutation from June 2012 to
December 2014 in our two institutions. The institutional
review board approved this retrospective study and waived
the need for written informed consent. The review com-
mittee of our two institutions approved the study in accor-
dance with the declaration of Helsinki.
In total, 267 cases were identified from our database.
Sixty-six cases were excluded: re-biopsy taken for recur-
rence (n = 28); extremely advanced cases in which the
main tumor could not be evaluated (n = 14); multifocal
primary tumors (n = 10); CT images taken before medica-
tion or surgery were not available (n = 7); tumors were
located mainly in the mediastinum (n = 4); and compli-
cated by severe infection (n = 2) and severe organizing
pneumonia (n = 1). Finally, a total of 201 patients were
included (Fig. 1). Of these cases, 91 underwent surgical
resection and the remaining 110 underwent a biopsy of the
primary tumor or metastatic lesions.
Data on age, gender, and smoking status were extracted
from each patient’s medical record. All patients were ethni-
cally Asian, and the mean age was 67.5 (range:
30–90) years. Almost half of the patients were female
(102/201, 50.7%) and non-smokers (95/183, 51.9%); smok-
ing history was not available for 18 cases.
Molecular testing and histological
examination
Molecular analysis was performed for all tumor samples to
determine the mutation status of EGFR exons 18, 19,
20, and 21 via real-time PCR or PCR-invader method, and
ALK gene rearrangement via fluorescence in situ hybridiza-
tion (FISH).1,2 The 201 patients were divided into three
subgroups: ALK (21 patients), EGFR (124 patients), and
non-ALK/EGFR (56 patients).
The histological predominant subtypes of the 91 surgi-
cally resected patients (ALK group, 8 patients; EGFR
group, 66 patients; and non-ALK/EGFR group, 17 patients)
were evaluated according to the 2015 World Health Orga-
nization (WHO) classification.17
Computed tomography (CT) analysis
CT examinations were performed using one of four CT
systems (Aquilion ONE and Aquilion 64, Toshiba, Nasu,
Japan; Somatom Definition Flash and Definition, Siemens,
Erlangen, Germany). The CT parameters were as follows:
detector collimation, 0.5–0.6 mm; beam pitch, 0.6–1.2;
Cases that have undergone testing for both ALK gene rearrangement 
and EGFR mutation (n = 267)
Re-biopsy for recurrence (n = 28)
Tumors located mainly in the mediastinum (n = 4)
Extremely advanced cases (n = 14)
Multifocal primary tumors (n = 10)
No CT examination before therapy (n = 7)
Complicated by severe infection (n = 2)
Complicated by organizing pneumonia (n = 1)
ALK gene rearrangement (ALK group, 21 cases), EGFR mutation
(EGFR group, 124 cases), and neither mutation
(non-ALK/EGFR group, 56 cases)
Figure 1 The selection process for the study cohort. CT, computed
tomography.
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rotation time, 0.5 seconds; tube voltage, 120 kVp; tube cur-
rent adjusted automatically with CT-automatic exposure
control; and a reconstruction kernel with a high-frequency
algorithm. The reconstruction thicknesses and intervals
were 1.0–2.0 mm and 1.0–2.0 mm on the pulmonary win-
dow setting (WS) (width, 1500 HU; level, −600 Hounsfield
units [HU]), and 3.0–4.0 mm and 2.4–4.0 mm on the
mediastinal WS (width, 300 HU; level, 25 HU), respec-
tively. Nonionic contrast medium (100 mL of Omnipaque
240, Daiichi-Sankyo, Tokyo, Japan; 100 mL of Oypalomin
300 and 65 mL of Oypalomin 370, Konica Minolta, Tokyo,
Japan) at a dose of 520–600 mgI/kg was used for CT
examination in 137 patients (68.2%).
Two of three experienced radiologists independently
evaluated the main tumor in terms of its size (the maxi-
mum axial diameter on pulmonary WS), type (solid, part-
solid GGN, or pure GGN based on the presence of GGO),
air bronchogram, cavity, pleural indentation, margin
(smooth/irregular, lobulated, or spiculated), site of the
lesion (right upper lobe, middle lobe, right lower lobe, left
upper lobe, or left lower lobe), location of the lesion (cen-
tral [involving segmental or more proximal bronchi] or
peripheral), and contrast-enhanced characteristics (homo-
geneous, heterogeneous, or ring-enhancement pattern, and
presence or absence of inner vessels on CT). In addition,
coexisting pulmonary emphysema (low attenuation areas
compared to normal lung parenchyma), fibrosis (reticular
opacities and honeycombing), pleural effusion, pulmonary
metastasis (lung nodules < 5 mm [military] and ≥ 5 mm
[scattered]) or lymphangitic metastasis, and lymphadenop-
athy (lymph nodes with a short axis ≥ 10 mm on the medi-
astinal WS) were also evaluated. When there was
interobserver disagreement, a conclusion was reached by
consensus.
Statistical analysis
All statistical analyses in this study were performed using
the SAS version 9.2. Comparisons between ALK-positive
and EGFR-positive cases, ALK-positive and non-ALK/
EGFR cases, and ALK-positive and non-ALK cases (includ-
ing both EGFR-positive and non-ALK/EGFR cases) were
performed using Fisher’s exact test for categorical variables
and the Student’s t-test for continuous variables. A multi-
variate logistic regression model was applied with factors
that showed a significant difference in univariate analysis.
Variables that showed a significant difference in multivari-
ate analysis were selected using a backward elimination
method. The dependent variable was mutation status, and
the independent variables were clinical and CT characteris-
tics. The Akaike information criterion was used to select
the most informative variables for a single parsimonious
model.
Interobserver agreement was assessed by computing the
κ coefficient and its 95% confidence interval (CI): κ
0.21–0.40 indicated fair agreement, κ 0.41–0.60 indicated
moderate agreement, κ 0.61–0.80 indicated substantial
agreement, and κ 0.81–1.00 indicated almost perfect
agreement.18
Results
Clinical and histological characteristics
The clinical characteristics of the patients are shown in
Table 1. Results of the t-test indicated that ALK-positive
patients were younger than EGFR-positive patients (mean
age 63  13 vs. 68  9 years, respectively; P = 0.0156)
and non-ALK cases (P = 0.0187). There was a significantly
higher proportion of women in the ALK group than in the
non-ALK/EGFR group (13/21, 62%, and 15/56, 27%,
respectively; P = 0.0043), and the proportion of patients
who had a history of light or never smoking was lower in
the ALK group than in the non-ALK/EGFR group
(P = 0.0039).
The histological predominant subtypes of the surgically
resected cases are shown in Table 2. The most common
was invasive adenocarcinoma with a predominantly papil-
lary subtype (28/91, 30.8%). EGFR-positive cases were
associated with a high frequency of papillary, lepidic, and
Table 1 Clinical patient characteristics
P
Characteristic ALK (n = 21) EGFR (n = 124)
Non-ALK/







Age† 30–80 (63  13) 46–88 (68  9) 45–90 (67  10) 0.0156 0.0979 0.0187
Gender, N (%) — — — 0.8472 0.0043 0.2798
Male 8 (38) 50 (40) 41 (73) — — —
Female 13 (62) 74 (60) 15 (27) — — —
Smoking
history‡
0 (0, 23) 0 (0, 21) 38 (7, 56) 0.6736 0.0039 0.4729
†Age (years), range (mean  SD). ‡Smoking history (pack-year), median (the first quartile, the third quartile). Values in bold indicate a statistically sig-
nificant result.
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minimally invasive adenocarcinoma as the predominant
subtypes (23, 15, and 14 of 66; 35%, 23%, and 21%, respec-
tively). In contrast, these subtypes were less frequent in the
ALK-positive cases, where the most predominant subtype
was acinar (3/8, 38%). The non-ALK/EGFR group showed
various predominant patterns, with the solid pattern being
the most frequent (5/17, 29%).
CT characteristics
The interobserver agreement was fair to almost perfect (κ
coefficient range: 0.379–0.910). The CT characteristics of








EGFR (n = 17)
Solid, N (%) 2 (25) 5 (8) 5 (29)
Papillary, N (%) 1 (13) 23 (35) 4 (24)
Micropapillary, N (%) 1 (13) 3 (5) 1 (6)
Acinar, N (%) 3 (38) 6 (9) 1 (6)
Lepidic, N (%) 0 (0) 15 (23) 1 (6)
Minimally invasive
adenocarcinoma, N (%)
0 (0) 14 (21) 1 (6)
Other, N (%) 1 (13) 0 (0) 4 (24)
Table 3 Computed tomography characteristics of the main mass and coexisting lung abnormalities
P
Characteristic ALK (n = 21) EGFR (n = 124)
Non-ALK/







Size† 14–78 (39  19) 9–68 (31  13) 9–115 (44  23) 0.0155 0.3548 0.3423
Type, N (%) — — — 0.0048 0.1183 0.0206
Solid 21 (100) 80 (65) 59 (89) — — —
Part-solid GGN 0 (0) 40 (32) 6 (11) — — —
Pure GGN 0 (0) 4 (3) 0 (0) — — —
Margin, N (%) — — — 0.1783 0.3698 0.5930
Irregular 14 (67) 99 (80) 31 (55) — — —
Smooth 7 (33) 25 (20) 25 (45) — — —
Spiculation, N (%) 6 (29) 57 (46) 15 (27) 0.1369 0.8755 0.3091
Lobulation, N (%) 8 (38) 30 (24) 19 (34) 0.1804 0.7329 0.2955
Air bronchogram, N (%) 6 (29) 71 (57) 16 (29) 0.0148 1.0000 0.0857
Cavity, N (%) 2 (10) 10 (8) 7 (13) 0.8224 0.7173 0.9906
Pleural indentation, N (%) 8 (38) 64 (52) 19 (34) 0.2519 0.7329 0.4850
Site of the lesion, N (%) — — — 0.7055 0.9730 0.8230
RUL 5 (24) 40 (32) 16 (29) — — —
ML 1 (5) 13 (10) 3 (5) — — —
RLL 6 (29) 22 (18) 13 (23) — — —
LUL 6 (29) 33 (27) 14 (25) — — —
LLL 3 (14) 16 (13) 10 (18) — — —
Location, N (%) — — — 0.0332 0.1916 0.0486
Central 8 (38) 22 (18) 13 (23) — — —
Peripheral 13 (62) 102 (82) 43 (77) — — —
Contrast enhancement
pattern, N (%)
— — — 0.7631 0.8535 0.8866
Homogeneous 3 (21) 25 (29) 6 (16) — — —
Heterogeneous 10 (71) 52 (61) 28 (74) — — —
Ringed 1 (7) 8 (9) 4 (11) — — —
Inner vessel, N (%) 4 (27) 9 (10) 7 (18) 0.0800 0.5049 0.1470
Lung metastasis
pattern, N (%)
— — — — — —
Miliary 3 (14) 17 (14) 2 (4) 0.9436 0.0893 0.6044
Scattered 3 (14) 15 (12) 5 (9) 0.7785 0.4926 0.6654
Lymphangitic 4 (19) 9 (7) 10 (18) 0.0803 0.9040 0.2473
Lymphadenopathy, N (%) 14 (67) 52 (42) 32 (57) 0.0353 0.4479 0.0827
Emphysema, N (%) 5 (24) 13 (10) 31 (55) 0.0868 0.0135 0.9489
Fibrosis, N (%) 2 (10) 7 (6) 9 (16) 0.4957 0.4646 0.9232
Pleural effusion, N (%) 3 (14) 18 (15) 12 (21) 0.9779 0.4809 0.7805
†Size (mm), range (mean  standard deviation). Values in bold indicate a statistically significant result. GGO, ground glass opacity; LLL, left lower
lobe; LUL, left upper lobe; ML, middle lobe; RLL, right lower lobe; RUL, right upper lobe.
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the ALK group that significantly differed from the EGFR
group were: a large mass (P = 0.0155), a solid mass
(P = 0.0048), no air bronchogram (P = 0.0148), central
location (P = 0.0322), and lymphadenopathy (P = 0.0353).
Coexisting emphysema was significantly less frequent in
the ALK group than in the non-ALK/EGFR group (24%
vs. 55%; P = 0.0135) (Table 3, Figs 2, 3).
Multivariate analysis using the Akaike information crite-
rion was performed including all clinical and CT variables;
the results are summarized in Table 4. Among the variables
analyzed, air bronchogram, emphysema, and a central
location were independent predictive factors of ALK gene
rearrangement status.
Discussion
In this study, we investigated the characteristics of clinical
and CT findings of NSCLC with ALK gene rearrangement.
We found that a relatively large solid mass without air
bronchogram was a significant characteristic CT finding
for NSCLC with ALK gene rearrangement. NSCLC with
ALK gene rearrangement was also more often associated
with a central location and lymphadenopathy when com-
pared to NSCLC with EGFR mutation; it was also more
often associated with pulmonary emphysema when com-
pared to non-ALK/EGFR NSCLC patients. Patients who
were younger, female, or had a light or no smoking history
were more likely to have NSCLC with ALK gene rearrange-
ment. These results are consistent with those of a previous
clinical study.6 None of the ALK-positive NSCLC cases in
this study showed a lepidic growth pattern as the predomi-
nant histologic subtype.
The genetic abnormalities involved in NSCLC can be
determined by specific analyses of histological samples
obtained by invasive procedures. However, Isaka et al.
reported that only approximately 50% of transbronchial
biopsy specimens contain sufficient amounts of DNA for
amplicon-based massively parallel sequencing.19 Therefore,
it would be beneficial to understand the clinical and radio-
logical features that might help distinguish the different
molecular subtypes in advance before invasive diagnostic
procedures are performed. Moreover, ALK gene rearrange-
ment and EGFR mutation are generally mutually
exclusive,7–9 and ALK gene rearrangement is less common.6
It is important to distinguish the clinical and radiological
findings of NSCLC with ALK gene rearrangement from
other types of NSCLC, because it may enable medical
oncologists to evaluate the consistency between these find-
ings and molecular testing results, and patients could then
receive potentially beneficial TKI therapy.
In the current study, pulmonary emphysema was less
commonly observed in patients with ALK gene rearrange-
ment than in those with non-ALK/EGFR NSCLC. This
result seems to reflect the fact that most of these patients
had a history of light or never smoking. However, coexist-
ing emphysema was an independent predictive factor of
ALK gene rearrangement status when compared to EGFR
mutation. A plausible reason for this is that EGFR muta-
tion status has a stronger association with non-emphysema
status.
There has been no consensus on the imaging findings of
ALK-positive NSCLC. Wang et al. reported that a relatively
large solid mass without “bubble-like lucency” was more
likely to be ALK-positive than EGFR-positive NSCLC.16 Ko
et al. reported that ALK-positive tumors were larger and
had a solid proportion when compared to non-ALK
tumors.11 Consistent with these findings, our results indi-
cate that a relatively large solid mass was a CT
Figure 2 Computed tomography images of an 80-year-old woman with adenocarcinoma with ALK gene rearrangement. (a) Lung window image
showing a large solid mass in the central area of the left upper lobe. Multiple scattered nodules suggest lung metastasis (arrows). (b) Mediastinal
window image showing lymphadenopathy (arrowheads).
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Figure 3 Computed tomography images of a 30-year-old woman with adenocarcinoma with ALK gene rearrangement. (a,b) Lung window images
show a solid mass with a spiculated (arrow) and lobulated (arrowhead) margin in the periphery of the left upper lobe. (c,d) Mediastinal window
images show the heterogeneous enhancement pattern of the mass. (e) High-power photomicrograph of the tumor show the acinar predominant
subtype (original magnification ×50; hematoxylin and eosin staining).
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characteristic of NSCLC with ALK gene rearrangement.
We found that air bronchogram occurred significantly less
frequently in NSCLC with ALK gene rearrangement.
According to previous studies, a more lobulated
margin,14,20 a less spiculated margin,13,14 or less pleural
indentation12,13 are characteristics of the main lesion. How-
ever, few articles have reported the significant inner or
margin characteristics of the main mass; thus, no consen-
sus on the significance of these observations has been
reached.
In this study, the main lesions of ALK-positive NSCLC
were more commonly located in the central region com-
pared to EGFR-positive or non-ALK NSCLC. Yamamoto
et al. similarly reported that ALK-positive tumors were
more commonly located in the central region, and that
there were fewer operable cases in ALK-positive than in
non-ALK NSCLC (8/47 and 44/123 cases, respectively).12
In our study, only 8 of the 21 cases underwent surgery.
Similar to our results, several articles have reported that
coexisting lymphadenopathy, which suggests lymph node
metastasis, is more often observed in patients with ALK-
positive NSCLC.14,16,21 This finding seems to reflect the fact
that patients with ALK-positive NSCLC have a poor
prognosis.
Histological examination is important for analyzing the
main tumor. Previous studies have shown that ALK-
positive NSCLC is associated with the solid predominant
subtype.10,16,22 Inamura et al. reported a relationship
between ALK-positive NSCLC and the papillary or acinar
subtypes.8 No consensus on the significance of these his-
tological characteristics has been reached; however, it
seems that lepidic predominant adenocarcinomas (adeno-
carcinoma in situ, minimally invasive adenocarcinoma,
and lepidic predominant invasive adenocarcinoma) are
less likely to develop ALK gene rearrangement. None of
the ALK-positive NSCLC cases in this study showed a
lepidic growth pattern as the predominant histological
subtype.
This study has several limitations. First, this was a retro-
spective study. Second, there were fewer NSCLC patients
in our sample with ALK gene rearrangement than with
EGFR-positive tumors; however, the prevalence of ALK gene
rearrangement in NSCLC patients is approximately 5%,6
while that of EGFR mutation is 40–80%.1 The results of mul-
tivariate regression analysis in our study require further veri-
fication because of the small number of ALK-positive
NSCLC patients in our sample. Selection bias may be an
issue, as we did not perform molecular testing in all NSCLC
patients. Our sample may also have included more advanced
cases that were considered for chemotherapy than would be
found in the general NSCLC population. However, we
believe that these limitations did not affect the main results
of this study.
NSCLC with ALK gene rearrangement is more likely to
develop in younger women with a history of light or never
smoking. The characteristic CT findings of NSCLC with
ALK gene rearrangement in comparison to EGFR mutation
were a large solid mass, less air bronchogram, a central
location, and lymphadenopathy. Combining these results
may assist clinicians to assess the likelihood of NSCLC
with ALK gene rearrangement.
Disclosure
No authors report any conflict of interest.
References
1 Lynch TJ, Bell DW, Sordella R et al. Activating mutations in
the epidermal growth factor receptor underlying
responsiveness of non-small-cell lung cancer to gefitinib. N
Engl J Med 2004; 350: 2129–39.
2 Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung
cancer: Correlation with clinical response to gefitinib
therapy. Science 2004; 304: 1497–500.
3 Soda M, Choi YL, Enomoto M et al. Identification of the
transforming EML4-ALK fusion gene in non-small-cell lung
cancer. Nature 2007; 448: 561–6.
4 Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or
chemotherapy for non-small-cell lung cancer with mutated
EGFR. N Engl J Med 2010; 362: 2380–8.
5 Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus
cisplatin plus docetaxel in patients with non-small-cell lung
cancer harbouring mutations of the epidermal growth factor
receptor (WJTOG3405): An open label, randomised phase
3 trial. Lancet Oncol 2010; 11: 121–8.
6 Solomon BJ, Mok T, Kim DW et al. First-line crizotinib
versus chemotherapy in ALK-positive lung cancer. N Engl J
Med 2014; 371: 2167–77.
7 Fukui T, Yatabe Y, Kobayashi Y et al. Clinicoradiologic
characteristics of patients with lung adenocarcinoma
harboring EML4-ALK fusion oncogene. Lung Cancer 2012;
77: 319–25.
Table 4 Multivariable logistic regression analyses
Characteristic Multivariate odds ratio (95% CI) P
ALK vs. EGFR
Air bronchogram (−) 3.508 (1.256–9.800) 0.0166
Emphysema (+) 2.933 (0.880–9.780) 0.0799
ALK vs. non-ALK/EGFR
Emphysema (−) 3.968 (1.277–12.332) 0.0172
ALK vs. non-ALK
Air bronchogram (−) 2.339 (0.868–6.299) 0.0929
Central location 2.550 (0.981–6.625) 0.0547
CI, confidence interval.
Thoracic Cancer (2019) © 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd 7
M. Mori et al. The characteristics of NSCLC with ALK
8 Inamura K, Takeuchi K, Togashi Y et al. EML4-ALK fusion
is linked to histological characteristics in a subset of lung
cancers. J Thorac Oncol 2008; 3: 13–7.
9 Wong DW, Leung EL, So KK et al. The EML4-ALK fusion
gene is involved in various histologic types of lung cancers
from nonsmokers with wild-type EGFR and KRAS. Cancer
2009; 115: 1723–33.
10 Kim H, Chung JH. Overview of clinicopathologic features of
ALK-rearranged lung adenocarcinoma and current
diagnostic testing for ALK rearrangement. Transl Lung
Cancer Res 2015; 4: 149–55.
11 Ko SJ, Lee YJ, Park JS et al. Epidermal growth factor
receptor mutations and anaplastic lymphoma kinase
rearrangements in lung cancer with nodular ground-glass
opacity. BMC Cancer 2014; 14: 312.
12 Yamamoto S, Korn RL, Oklu R et al. ALK molecular
phenotype in non–small cell lung cancer: CT radiogenomic
characterization. Radiology 2014; 272: 568–76.
13 Zhou JY, Zheng J, Yu ZF et al. Comparative analysis of
clinicoradiologic characteristics of lung adenocarcinomas
with ALK rearrangements or EGFR mutations. Eur Radiol
2015; 25: 1257–66.
14 Choi C-M, Kim MY, Hwang HJ, Lee JB, Kim WS. Advanced
adenocarcinoma of the lung: Comparison of CT
characteristics of patients with anaplastic lymphoma kinase
gene rearrangement and those with epidermal growth factor
receptor mutation. Radiology 2015; 275: 272–9.
15 Rizzo S, Petrella F, Buscarino V et al. CT radiogenomic
characterization of EGFR, K-RAS, and ALK mutations in
non-small cell lung cancer. Eur Radiol 2016; 26: 32–42.
16 Wang H, Schabath MB, Liu Y et al. Clinical and CT
characteristics of surgically resected lung adenocarcinomas
harboring ALK rearrangements or EGFR mutations. Eur J
Radiol 2016; 85: 1934–40.
17 Travis WD, Brambilla E, Nicholson AG et al. The 2015
World Health Organization Classification of Lung
Tumors: Impact of genetic, clinical and radiologic
advances since the 2004 classification. J Thorac Oncol
2015; 10: 1243–60.
18 Landis JR, Koch GG. The measurement of observer
agreement for categorical data. Biometrics 1977; 33:
159–74.
19 Isaka M, Serizawa M, Kenmotsu H et al. Comparison of
clinically relevant mutation profiles between preoperative
biopsy and corresponding surgically resected specimens in
Japanese patients with non-small-cell lung cancer by
amplicon-based massively parallel sequencing. Clin Lung
Cancer 2017; 18: 519–26 e1.
20 Kim TJ, Lee CT, Jheon SH, Park JS, Chung JH. Radiologic
characteristics of surgically resected non-small cell lung
cancer with ALK rearrangement or EGFR mutations. Ann
Thorac Surg 2016; 101: 473–80.
21 Halpenny DF, Riely GJ, Hayes S et al. Are there imaging
characteristics associated with lung adenocarcinomas harboring
ALK rearrangements? Lung Cancer 2014; 86: 190–4.
22 Dong YJ, Cai YR, Zhou LJ et al. Association between the
histological subtype of lung adenocarcinoma, EGFR/KRAS
mutation status and the ALK rearrangement according to
the novel IASLC/ATS/ERS classification. Oncol Lett 2016;
11: 2552–8.
8 Thoracic Cancer (2019) © 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd
The characteristics of NSCLC with ALK M. Mori et al.
